I agree that this site is using cookies. You can find further informations here.
X
Okpara, Chinyere J
45  results:
Search for persons X
?
1

Avoidance of care: how health-care affordability influenced..:

Okpara, Chinyere J ; Divers, Jasmin ; Winner, Megan
American Journal of Epidemiology.  193 (2024)  7 - p. 987-995 , 2024
Link: https://doi.org/10.1093/..
 
?
2

Comparative results of focal-cryoablation and stereotactic ..:

Monaco, Ashley ; Sommer, Jessica ; Okpara, Chinyere...
International Urology and Nephrology.  54 (2022)  10 - p. 2529-2535 , 2022
Link: https://doi.org/10.1007/..
 
?
3

891. Challenging the Dogma of Beta-Lactam Allergies: Impact..:

Holzworth, Abriana ; Blum, Sharon ; Bosco, Michael...
Open Forum Infectious Diseases.  9 (2022)  Supplement_2 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
4

Outcomes of Breast Cancer Patients Treated with Chemotherap..:

Marks, Douglas K ; Budhathoki, Nibash ; Kucharczyk, John...
The Oncologist.  27 (2022)  2 - p. 89-96 , 2022
Link: https://doi.org/10.1093/..
 
?
5

Beyond Aggravating and Mitigating Factors: The Analysis of ..:

Okpara, Chinyere ; Hendricks, Audrey E. ; Cobb, Loren
Justice Evaluation Journal.  4 (2021)  2 - p. 281-315 , 2021
Link: https://doi.org/10.1080/..
 
?
6

Pembrolizumab With or Without Lenvatinib for First-Line Met..:

Yang, James Chih-Hsin ; Han, Baohui ; De La Mora Jiménez, Emmanuel...
Journal of Thoracic Oncology.  19 (2024)  6 - p. 941-953 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Lenvatinib plus pembrolizumab for patients with previously ..:

González-Martín, Antonio ; Chung, Hyun Cheol ; Saada-Bouzid, Esma...
Gynecologic Oncology.  186 (2024)  - p. 182-190 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Pembrolizumab with or Without Lenvatinib as First-line Ther..:

Matsubara, Nobuaki ; de Wit, Ronald ; Balar, Arjun Vasant...
European Urology.  85 (2024)  3 - p. 229-238 , 2024
Link: https://doi.org/10.1016/..
 
?
9

Corrigendum: Phase 3 CLEAR study in patients with advanced ..:

Grünwald, Viktor ; Powles, Thomas ; Eto, Masatoshi...
Frontiers in Oncology.  13 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
10

Lenvatinib plus Pembrolizumab Following Immune Checkpoint I..:

Lee, Chung-Han ; Yogesh Shah, Amishi ; Rao, Arpit...
European Urology.  , 2024
Link: https://doi.org/10.1016/..
 
?
11

Lenvatinib plus pembrolizumab for patients with previously ..:

Chung, Hyun Cheol ; Saada‐Bouzid, Esma ; Longo, Federico...
Cancer.  , 2024
Link: https://doi.org/10.1002/..
 
?
12

Characterization and Management of Adverse Reactions in Pat..:

Colombo, Nicoletta ; Lorusso, Domenica ; Monk, Bradley J...
The Oncologist.  29 (2023)  1 - p. 25-35 , 2023
Link: https://doi.org/10.1093/..
 
?
13

Phase 3 CLEAR study in patients with advanced renal cell ca..:

Grünwald, Viktor ; Powles, Thomas ; Eto, Masatoshi...
Frontiers in Oncology.  13 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
14

Lenvatinib dose, efficacy, and safety in the treatment of m..:

Motzer, Robert J. ; Taylor, Matthew H. ; Evans, Thomas R. Jeffry...
Expert Review of Anticancer Therapy.  22 (2022)  4 - p. 383-400 , 2022
Link: https://doi.org/10.1080/..
 
?
15

Paediatric Strategy Forum for medicinal product development..:

Pearson, Andrew DJ. ; Gaspar, Nathalie ; Janeway, Katherine...
European Journal of Cancer.  173 (2022)  - p. 71-90 , 2022
Link: https://doi.org/10.1016/..
 
1-15